Gene Variant May Predict Sudden Cardiac Death Risk for Blacks
Researchers at Duke University Medical Center have pinpointed a common gene variant in blacks that may be associated with the development of life-threatening heart arrhythmias. The finding may help determine which patients are likely to benefit most from implantable cardio-defibrillators (ICDs).
May 10, 2011
Bypass Surgery Should Be Considered for Some Heart Failure Patients
The first study to compare contemporary approaches to surgery and medical therapy for heart failure caused by clogged coronary arteries found coronary bypass surgery should be considered in addition to medical therapy, according to researchers at Duke Clinical Research Institute. The findings were presented today at the American College of Cardiology's Annual Scientific Session and simultaneously published online in the New England Journal of Medicine.
Apr. 4, 2011
Implantable Heart Defibrillators Too Widely Used in High-Risk Patients
More than one in five patients who receive implantable cardioverter-defibrillators (ICDs) do not meet evidence-based guidelines to receive them, significantly increasing their risk of complications and death, according to a new study published in the Journal of the American Medical Association and led by the Duke Clinical Research Institute.
Jan. 5, 2011
Statewide Program Speeds Up Heart Attack Care in North Carolina
A program designed to speed up heart attack care has led to significant improvement in the quality of care for heart attack patients after it was extended across North Carolina last year, according to researchers at Duke University Medical Center.
Nov. 16, 2010
Major Study Shows Ability of New Agent to Prevent Strokes in Patients with Atrial Fibrillation
In the primary result from the largest double-blind study ever completed to assess a drug’s effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be superior to warfarin, the current standard for treatment of atrial fibrillation, while patients in the study were taking study drug. However, the full intention-to-treat analysis, which includes patients who discontinued study drug, showed that rivaroxaban was non inferior to warfarin for the prevention of stroke or blood clots but did not demonstrate statistical superiority.
Nov. 15, 2010